alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › agonists

agonists

286 studies tagged agonists, dated 1994-05-01 to 2026-10-30. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration 2026-10-30
  2. Beyond Glycemic Control: The Pleiotropic Role of GLP-1RAs and Melatonin in Combating Neuroinflammation and Mitochondrial Dysfunction 2026-10-28
  3. PFKFB3 inhibition restores β-cell responsiveness to acetylcholine in a 3xTg-AD pancreatic tissue-slice model 2026-10-07

Studies

286 studies carry this tag.

Date range

1994 to 2026

Top journals

  • International journal of molecular sciences 10
  • Journal of Alzheimer's disease : JAD 10
  • Neuropharmacology 10
  • European journal of pharmacology 8
  • Neurobiology of aging 6

177 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. 3 Biotech 2021-03-20 Drug development

    Alzheimer's disease (AD) is a progressive neurodegenerative disease, also regarded as "type 3 diabetes" for the last few years because of the brain insulin resistance (IR) and dysregulation of insulin signaling in the brain, which can further promote pathological progression of AD.

  2. GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Molecular metabolism 2021-02-06 Drug development

    We revealed GLP-1's capacity to regulate astrocytic glycolysis, providing mechanistic insight into one of its neuroprotective roles in AD and support for the feasibility of energy regulation treatments for AD.

  3. RETRACTED: Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease

    ⚠ Retracted — do not rely on it alzhub usefulness score 16 out of 100. International journal of molecular sciences 2021-01-16 Drug development

    Recent clinical and epidemiological studies support the contention that diabetes mellitus (DM) is a strong risk factor for the development of Alzheimer's disease (AD).

  4. GLP-1 mimetics and cognition

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Life sciences 2020-10-26 Drug development

    Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic drugs that improve the glycaemia via several molecular pathways.

  5. Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2020-10-14 Drug development

    Our results provide a clue for the hypothesis that autophagy enhancement and apoptosis inhibition may be involved in the effect of semaglutide to protect against Aβ 25-35 .

  6. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Biochemical pharmacology 2020-08-02 Drug development

    Among the more promising treatments proposed for Alzheimer's disease (AD) and Parkinson's disease (PD) are those reducing brain insulin resistance.

  7. Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Lancet. Neurology 2020-07-27 Disease mechanisms

    Insulin is a peptide secreted by the pancreas and plays an important role in the regulation of glucose metabolism in peripheral tissues.

  8. The role of GLP-1/GIP receptor agonists in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2020-06 Drug development

    Different concentrations of OA were able to induce apoptosis of SH-SY5Y cells in a dose-dependent manner.

  9. Obesity and Age-Related Changes in the Brain of the Zucker Lepr fa/fa Rats

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Nutrients 2020-05-09 Risk factors

    Metabolic syndrome (MetS) is an association between obesity, dyslipidemia, hyperglycemia, hypertension, and insulin resistance.

  10. Could metformin be therapeutically useful in Huntington's disease?

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Reviews in the neurosciences 2020-04-28 Drug development

    Emerging evidence suggest that dimethylbiguanide (metformin), a first-line drug for type 2 diabetes mellitus, could be neuroprotective in a range of brain pathologies, which include neurodegenerative diseases and brain injury.

  11. Recent advances in understanding the role of glucagon-like peptide 1

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. F1000Research 2020-04-06 Drug development

    The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the incretin effect during the postprandial period and the subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes (T2D) led to new therapeutic strategies being developed for T2D treatment based on GLP-1 action.

  12. Brain insulin resistance: role in neurodegenerative disease and potential for targeting

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Expert opinion on investigational drugs 2020-03-16 Drug development

    This review evaluates the novel strategy of treating Alzheimer's and Parkinson's disease (AD and PD) withdrugs that initially have been developed to treat type 2 diabetes.

  13. Liraglutide Protects Against Brain Amyloid-β 1-42 Accumulation in Female Mice with Early Alzheimer's Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. International journal of molecular sciences 2020-03-04 Drug development

    Alzheimer's disease (AD) is the most common form of dementia worldwide, being characterized by the deposition of senile plaques, neurofibrillary tangles (enriched in the amyloid beta (Aβ) peptide and hyperphosphorylated tau (p-tau), respectively) and memory loss.

  14. Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. International Journal of Molecular Sciences 2020-03-03 Drug development

    Neuronal insulin resistance is a significant feature of Alzheimer's disease (AD).

  15. Metformin and trimetazidine ameliorate diabetes-induced cognitive impediment in status epileptic rats

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Epilepsy & behavior : E&B 2020-01-27 Drug development

    Patients with diabetes and epilepsy are more prone to cognitive impairment, dementia, and even Alzheimer's disease.

  16. Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. International journal of obesity (2005) 2020-01-21 Drug development

    Liraglutide might slow down memory function decline in diabetic patients in early, and possibly preclinical stages of the disease.

  17. The novel GLP‐1/GIP analogue DA5‐CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Brain and Behavior 2020-01-20 Drug development

    Our results demonstrate that DA5‐CH has neuroprotective effects in the STZ‐induced animal model and that DA5‐CH has potential to treat neurodegenerative disorders such as AD.

  18. Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. American journal of Alzheimer's disease and other dementias 2020-01-01 Drug development

    Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered.

  19. The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. American journal of Alzheimer's disease and other dementias 2020-01-01 Drug development

    Alzheimer's disease (AD) is a neurodegenerative disorder for which there is no cure.

  20. Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2020-01-01 Drug development

    Vildagliptin (Vilda), a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been highlighted as a promising therapeutic agent for neurodegenerative diseases as Alzheimer's and Parkinson's diseases.

  21. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Peptides 2019-11-06 Drug development

    Glucose-dependent Insulinotropic polypeptide (GIP) is a peptide hormone of the incretin family.

  22. Diabetes drugs in the fight against Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Ageing research reviews 2019-07-19 Drug development

    Alzheimer's disease (AD) is the most prevalent form of dementia, particularly in old age subjects.

  23. Approach Toward Diabetes Treatment in the Elderly

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Sisli Etfal Hastanesi tip bulteni 2019-06-25 Drug development

    Concomitant diseases in elderly individuals with diabetes (renal failure, heart failure, ischemic heart disease, stroke, urinary incontinence, cognitive impairment, dementia, sarcopenia, and osteoporosis) make diabetes management difficult.

  24. The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosis

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Life sciences 2019-06-13 Drug development

    These data suggest that the neuroprotective effects of liraglutide on diabetes-induced cognitive impairments are associated with the improvements of hippocampal synapses and inhibition of neuronal apoptosis.

  25. DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuropharmacology 2019-06-12 Drug development

    Glucagon-like peptide-1 (GLP-1) signaling in the brain plays an important role in the regulation of glucose metabolism, which is impaired in Alzheimer's disease (AD).

  26. Chenodeoxycholic Acid Ameliorates AlCl 3 -Induced Alzheimer's Disease Neurotoxicity and Cognitive Deterioration via Enhanced Insulin Signaling in Rats

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Molecules (Basel, Switzerland) 2019-05-24 Drug development

    Insulin resistance is a major risk factor for Alzheimer's disease (AD).

  27. Glucagon-Like Peptide-1 Cleavage Product Improves Cognitive Function in a Mouse Model of Down Syndrome

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. eNeuro 2019-05-15 Drug development

    Currently there is no effective therapy available for cognitive impairments in Down syndrome (DS), one of the most prevalent forms of intellectual disability in humans associated with the chromosomes 21 trisomy.

  28. Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5×FAD mouse model of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Behavioural brain research 2019-05-10 Drug development

    The role of mitochondrial dysfunction has been well-documented in Alzheimer's disease (AD).

  29. Pancreatic islet (of Langerhans) revisited

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Histology and histopathology 2019-04-25 Drug development

    One hundred and fifty years ago, Paul Langerhans described what would come to be known as pancreatic 'islet of Langerhans'.

  30. Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in aging neuroscience 2019-04-24 Drug development

    Type 2 diabetes is a risk factor for developing Alzheimer's disease (AD).

  31. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Trials 2019-04-03 Drug development

    Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells.

  32. GLP-1's role in neuroprotection: a systematic review

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Brain injury 2019-04-02 Drug development

    Recent literature shows that GLP-1 and its agonists, DPP-4 inhibitors and combined GLP-1/GIP molecules are effective in partially or fully reversing the effects of neurotoxic compounds, neurovascular complications of diabetes, neuropathological changes related with Alzheimer's disease, Parkinson's disease or vascular occlusion.

  33. Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. CNS drugs 2019-03-01 Drug development

    The current absence of effective treatments for Alzheimer's disease (AD) and Parkinson's disease (PD) reflects an incomplete knowledge of the underlying disease processes.

  34. Liraglutide and its Neuroprotective Properties-Focus on Possible Biochemical Mechanisms in Alzheimer's Disease and Cerebral Ischemic Events

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. International journal of molecular sciences 2019-02-28 Drug development

    Liraglutide is a GLP-1 analog (glucagon like peptide-1) used primarily in the treatment of diabetes mellitus type 2 (DM2) and obesity.

  35. Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Biochemical and biophysical research communications 2019-02-14 Drug development

    Dulaglutide, a novel long-acting glucagon-like peptide 1 (GLP-1) receptor agonist, is an incretin mimetic approved for type 2 diabetes mellitus (T2DM) treatment.

  36. Early-Stage Alzheimer’s Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer s Disease 2019-02-12 Drug development

    In MCI/AD, both the CSF and serum samples had significantly elevated mean levels of C-peptide and an incretin, and reduced expression of Visfatin, whereas only CSF showed significant reductions in insulin and leptin and only serum had increased glucagon, PAI-1, and ghrelin.

  37. Expression of GLP-1 receptors in insulin-containing interneurons of rat cerebral cortex

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Diabetologia 2019-01-12 Drug development

    Single-cell digital PCR revealed GLP-1 receptor expression in neurogliaform cells and showed that copy numbers of mRNA of the Glp1r gene in hyperglycaemia exceeded those in hypoglycaemia by 9.6 times (p < 0.008).

  38. Liraglutide Ameliorates Hyperhomocysteinemia-Induced Alzheimer-Like Pathology and Memory Deficits in Rats via Multi-molecular Targeting

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Neuroscience bulletin 2019-01-10 Drug development

    Hyperhomocysteinemia (Hhcy) is an independent risk factor for Alzheimer's disease (AD), and insulin-resistance is commonly seen in patients with Hhcy.

  39. A Pilot Study of Exenatide Actions in Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 67 out of 100. Current Alzheimer research 2019-01-01 Drug development

    The positive finding of lower EV Aβ42 supports emerging evidence that plasma neuronal EVs provide an effective platform for demonstrating biomarker responses in clinical trials in AD.

  40. Geniposide-mediated protection against amyloid deposition and behavioral impairment correlates with downregulation of mTOR signaling and enhanced autophagy in a mouse model of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Aging 2019-01-01 Drug development

    Geniposide, an iridoid glycoside extract from the gardenia fruit, is used in traditional Chinese medicine to alleviate symptoms of liver and inflammatory diseases.

  41. Protective Effects of Incretin Against Age-Related Diseases

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Current drug delivery 2019 Drug development

    Incretin contains two peptides named glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

  42. Therapeutic Approaches to Alzheimer's Type of Dementia: A Focus on FGF21 Mediated Neuroprotection

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Current pharmaceutical design 2019 Risk factors

    Neurodegenerative disorders are the most devastating disorder of the nervous system.

  43. Therapeutic Strategies for Alzheimer's Disease in the View of Diabetes Mellitus

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Advances in experimental medicine and biology 2019 Drug development

    Recently, Alzheimer's disease (AD) is understood as "diabetes of the brain" or "type 3 diabetes."

  44. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuropharmacology 2018-11-11 Drug development

    Obesity and type 2 diabetes mellitus (T2DM) are important risk factors for Alzheimer's disease (AD).

  45. Prolonged Drug-Releasing Fibers Attenuate Alzheimer's Disease-like Pathogenesis

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. ACS applied materials & interfaces 2018-10-22 Drug development

    Delivering drugs and agents to the brain is a huge challenge, especially for chronic neurodegenerative disorders, such as Alzheimer's disease (AD).

  46. Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Behavioural brain research 2018-08-09 Drug development

    Insulin resistance (IR) is a metabolic state preceding development of type 2 diabetes (DM2), cardiovascular disease, and neurodegenerative disorders, including Alzheimer's Disease (AD).

  47. Liraglutide for psychiatric disorders: clinical evidence and challenges

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Hormone molecular biology and clinical investigation 2018-07-18 Drug development

    Obesity and diabetes are both risk factors and consequences of psychiatric disorders.

  48. iPSC-derived familial Alzheimer's PSEN2 N141I cholinergic neurons exhibit mutation-dependent molecular pathology corrected by insulin signaling

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Molecular neurodegeneration 2018-06-26 Risk genes beyond APOE

    We report herein that wildtype, PSEN2 N141I and CRISPR/Cas9-corrected iPSC-derived BFCNs (and their precursors) show indistinguishable insulin signaling profiles as determined by the phosphorylation of canonical insulin signaling pathway molecules.

  49. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Nature medicine 2018-06-11 Drug development

    Activation of microglia by classical inflammatory mediators can convert astrocytes into a neurotoxic A1 phenotype in a variety of neurological diseases 1,2 .

  50. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Brain research 2018-04-27 Drug development

    Recent studies indicate that metabolic disorders such as diabetes and obesity are a major risk factor of psychiatric diseases.

From across this tag

7 of the 286 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 7. The same 7 appear here every time.

All topic tags with their study counts